JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.

Home
Signaling Pathways

Signaling Pathways

A3012 Ruxolitinib (INCB018424)
4 Citation

Target: JAK

Summary: JAK inhibitor

insoluble in H2O; ≥15.32 mg/mL
A3018 Trametinib (GSK1120212)
7 Citation

Target: MEK

Summary: MEK1 and MEK2 inhibitor, potent and selective

insoluble in H2O; insoluble in EtOH; ≥15.38 mg/mL
A4112 Barasertib (AZD1152-HQPA)
3 Citation

Target: Aurora Kinases

Summary: Aurora Kinase B inhibitor, Potent and selective

≥25.4 mg/mL
A1905 3-Deazaneplanocin,DZNep
6 Citation

Target: Hydrolase

Summary: S-adenosylhomocysteine and EZH2 inhibitor

insoluble in EtOH; ≥17.07 mg/mL
A3573 LY2801653

Target: MET

Summary: MET inhibitor

≥27.65 mg/mL
A8885 Ro 3306
4 Citation

Target: Cyclin-Dependent Kinases

Summary: An ATP-competitive, potent CDK1 inhibitor

insoluble in EtOH; insoluble in H2O; ≥4.39 mg/mL
B4894 SP2509

Target: Histone Demethylases

Summary: Demethylase 1 (LSD1) antagonist, novel Lysine-specific

insoluble in H2O; insoluble in EtOH; ≥19.45 mg/mL
B4900 Indoximod (NLG-8189)

Summary: Indoleamine 2,3-dioxygenase (IDO) pathway inhibitor

insoluble in DMSO; insoluble in EtOH; ≥1.12 mg/mL
B5846 Radotinib(IY-5511)

Target: PDGFR|Bcr-Abl

Summary: Bcr-Abl tyrosine kinase inhibitor

≥13.73 mg/mL
B6008 BPTES

Target: Glutaminases

Summary: GLS inhibitor

insoluble in H2O; insoluble in EtOH; ≥18 mg/mL